Terpos, Evangelos http://orcid.org/0000-0001-5133-1422
Mikhael, Joseph
Hajek, Roman http://orcid.org/0000-0001-6955-6267
Chari, Ajai
Zweegman, Sonja
Lee, Hans C.
Mateos, María-Victoria http://orcid.org/0000-0003-2390-1218
Larocca, Alessandra http://orcid.org/0000-0002-2070-3702
Ramasamy, Karthik
Kaiser, Martin http://orcid.org/0000-0002-3677-4804
Cook, Gordon
Weisel, Katja C. http://orcid.org/0000-0001-9422-6614
Costello, Caitlin L.
Elliott, Jennifer
Palumbo, Antonio http://orcid.org/0000-0002-1763-6609
Usmani, Saad Z.
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Article History
Received: 9 November 2020
Revised: 22 January 2021
Accepted: 28 January 2021
First Online: 18 February 2021
Conflict of interest
: E.T.: Honoraria and research funding from Amgen and Sanofi; honoraria from BMS and Celgene; honoraria, travel expenses, and research funding from Genesis, Janssen, and Takeda. J.M.: Consultancy for Amgen, Celgene, GSK, Janssen, Karyopharm, Sanofi, and Takeda. R.H.: Consultancy, honoraria, membership on an entity’s board of directors or advisory committees and research funding for Janssen, Amgen, Celgene and Bristol-Myers Squibb; consultancy for AbbVie; consultancy and research funding for Novartis; consultancy, honoraria and membership on an entity’s Board of Directors or advisory committees for PharmaMar; consultancy, consultant or advisory relationship, honoraria, membership on an entity’s board of directors or advisory committees and research funding for Takeda. A.C.: Consultancy for Janssen, Celgene, Novartis, Amgen, Bristol-Myers Squibb, Takeda, Antengene, and Secura Bio; advisory boards with Janssen, Celgene, Novartis, Amgen, Karyopharm, Sanofi, Seattle Genetics, Oncopeptides, GlaxoSmithKline, and Secura Bio; research funding from Janssen, Celgene, Novartis, Amgen, Pharmacyclics, Seattle Genetics, and Takeda. S.Z.: Research funding from and advisory boards for Takeda, Celgene, and Janssen. H.C.L.: Membership on an entity’s board of directors or advisory committees for Amgen, Sanofi, Celgene, Genentech, GlaxoSmithKline plc, Takeda, and Janssen; research funding from Takeda, Amgen, Janssen, Celgene, GlaxoSmithKline plc, and Daiichi Sankyo. M.V.M.: Personal fees from Takeda, Janssen, Amgen, Celgene, GSK, and Abbvie. A.L.: Advisory boards for Bristol-Myers Squibb, Celgene, Janssen, and Takeda; honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and GSK. K.R.: Takeda: honoraria, research funding; Amgen: honoraria; Janssen: honoraria; Celgene: honoraria, research funding; Adaptive Biotech: Honoraria; Oncopeptides: Honoraria. M.K.: Consultancy for Amgen, Janssen, Takeda, Celgene/BMS, GSK, Karyopharm, and Abbvie; institutional research funding from Janssen and Celgene/BMS; travel support from Janssen and Takeda. G.C.: Consultancy, honoraria, research funding and speakers bureau for Janssen, Takeda and Celgene; consultancy, honoraria and speakers bureau for Sanofi and Karyopharm. K.C.W.: Advisory boards for Amgen, Bristol-Myers Squibb, Adaptive Biotech, Celgene, Janssen, Juno, Takeda, Sanofi; honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; research funding from Amgen, Celgene, Janssen, and Sanofi. C.L.C.: Honoraria and research funding for Takeda; research funding for Janssen; consultancy, honoraria and research funding for Celgene. J.E. and A.P.: Employment, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. S.Z.U.: Consultancy, patents & royalties, research funding and speakers bureau for Amgen, Celgene, Janssen and Takeda; patents & royalties and research funding for Array Biopharma and Pharmacyclics; consultancy and research funding for Bristol-Myers Squibb and Merck; patents & royalties, research funding and speakers bureau for Sanofi; consultancy for Skyline DX.